Literature DB >> 8164648

Biological activity of the growth factor-induced cytokine N51: structure-function analysis using N51/Interleukin-8 chimeric molecules.

J N Heinrich1, E C O'Rourke, L Chen, H Gray, K S Dorfman, R Bravo.   

Abstract

The immediate-early gene N51/KC encodes a protein which following expression in the baculovirus system and purification to apparent homogeneity is able to induce chemotaxis and intracellular Ca2+ flux, to compete for 125I-labeled interleukin-8 (IL-8) binding, and upon iodination, to bind specifically to human neutrophils. The activity of N51/KC can be distinguished from that of IL-8 by a number of criteria. First, at equivalent concentrations, the specific binding of [125I]N51/KC to human neutrophils is about 10 times less than that of [125I]IL-8. Second, the competition studies of [125I]IL-8 with IL-8 define a single class of high-affinity receptors, while the presence of both a high- and a low-affinity class of receptors is defined by N51/KC. Third, although the changes in intracellular Ca2+ of fura-2/AM-preloaded human neutrophils elicited by N51/KC and IL-8 are similar, pretreatment of the cells with N51/KC did not result in a loss of response to a subsequent treatment with IL-8; in contrast, treatment with IL-8 did result in the subsequent desensitization to N51/KC. To further characterize N51/KC, mutants and hybrids of N51/KC and IL-8 were produced and analyzed for the ability to compete for [125I]IL-8 binding and elicit intracellular Ca2+ changes in human neutrophils. Two important observations came from these studies. First, the N51/IL-8I hybrid in which the N51/KC sequence between cysteines 2 and 3 (or first disulfide bond) is replaced by the corresponding sequence in IL-8 shows IL-8-like properties, indicating that this region is important for specific receptor recognition. Second, the N51 delta III and IL-8 delta III C-terminus deletion mutants were biologically inactive, but the hybrid molecules N51/IL-8III and IL-8/N51III, in which the C termini were exchanged, had biological activities similar to that of the wild-type molecules, demonstrating that the presence of the C terminus is essential for the biological activity of these chemokines but does not confer receptor specificity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8164648      PMCID: PMC358653          DOI: 10.1128/mcb.14.5.2849-2861.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  41 in total

1.  Identification and characterization of macrophage inflammatory protein 2.

Authors:  S D Wolpe; B Sherry; D Juers; G Davatelis; R W Yurt; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

2.  Cloning and sequence of a secretory protein induced by growth factors in mouse fibroblasts.

Authors:  R P Ryseck; H MacDonald-Bravo; M G Mattei; R Bravo
Journal:  Exp Cell Res       Date:  1989-01       Impact factor: 3.905

3.  Silver staining of proteins in polyacrylamide gels.

Authors:  W Wray; T Boulikas; V P Wray; R Hancock
Journal:  Anal Biochem       Date:  1981-11-15       Impact factor: 3.365

4.  Molecular cloning of gene sequences regulated by platelet-derived growth factor.

Authors:  B H Cochran; A C Reffel; C D Stiles
Journal:  Cell       Date:  1983-07       Impact factor: 41.582

5.  Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist.

Authors:  M Thelen; P Peveri; P Kernen; V von Tscharner; A Walz; M Baggiolini
Journal:  FASEB J       Date:  1988-08       Impact factor: 5.191

6.  Three-dimensional structure of interleukin 8 in solution.

Authors:  G M Clore; E Appella; M Yamada; K Matsushima; A M Gronenborn
Journal:  Biochemistry       Date:  1990-02-20       Impact factor: 3.162

7.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.

Authors:  A E Bolton; W M Hunter
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

8.  Complexity of the early genetic response to growth factors in mouse fibroblasts.

Authors:  J M Almendral; D Sommer; H Macdonald-Bravo; J Burckhardt; J Perera; R Bravo
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

9.  Lipopolysaccharide-stimulated human monocytes secrete, apart from neutrophil-activating peptide 1/interleukin 8, a second neutrophil-activating protein. NH2-terminal amino acid sequence identity with melanoma growth stimulatory activity.

Authors:  J M Schröder; N L Persoon; E Christophers
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

10.  Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin.

Authors:  A Richmond; E Balentien; H G Thomas; G Flaggs; D E Barton; J Spiess; R Bordoni; U Francke; R Derynck
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

View more
  4 in total

1.  Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes.

Authors:  M Tani; M E Fuentes; J W Peterson; B D Trapp; S K Durham; J K Loy; R Bravo; R M Ransohoff; S A Lira
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

2.  Site-directed mutagenesis of monocyte chemoattractant protein-1 identifies two regions of the polypeptide essential for biological activity.

Authors:  C J Beall; S Mahajan; D E Kuhn; P E Kolattukudy
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

3.  Fortilin binds Ca2+ and blocks Ca2+-dependent apoptosis in vivo.

Authors:  Potchanapond Graidist; Michio Yazawa; Moltira Tonganunt; Akiko Nakatomi; Curtis Chun-Jen Lin; Jui-Yoa Chang; Amornrat Phongdara; Ken Fujise
Journal:  Biochem J       Date:  2007-12-01       Impact factor: 3.857

4.  Expression of the chemokine N51/KC in the thymus and epidermis of transgenic mice results in marked infiltration of a single class of inflammatory cells.

Authors:  S A Lira; P Zalamea; J N Heinrich; M E Fuentes; D Carrasco; A C Lewin; D S Barton; S Durham; R Bravo
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.